Stocktoria

Fulcrum Therapeutics, Inc. FULC

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2019-07-18

Fulcrum Therapeutics, Inc. statistics & valuation

Market cap$253.2M
P / B0.7×
Return on equity-21.5%
Return on capital-24%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
20182019202020212022202320242025
Operating margin (%)
-811.60% -423.00% -1774.90% -3945.20% -27.40% 20182019202020212022202320242025
Return on equity (%)
-94.90% -74.40% -38.20% -55.20% -41.40% -4.00% -21.50% 20182019202020212022202320242025
Shares outstanding
1.6M 22.7M 27.9M 40.6M 52.1M 61.9M 54.0M 66.6M 20182019202020212022202320242025
Net debt ($)
20182019202020212022202320242025
Share buybacks ($)
20182019202020212022202320242025
Return on assets (%)
-38.00% -74.90% -54.70% -34.40% -48.50% -37.80% -3.70% -20.40% 20182019202020212022202320242025
Free cash flow margin (%)
-623.30% -418.50% -1561.20% -3261.10% -3.10% 20182019202020212022202320242025
Debt / equity (×)
20182019202020212022202320242025
EPS ($)
-$2.29 -$2.44 -$1.59 -$0.16 -$1.18 20182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin—-27.4%-3945.2%-1774.9%-423.0%-811.6%——
Net margin—-12.2%-3470.1%-1732.4%-421.9%-802.7%——
FCF margin—-3.1%-3261.1%-1561.2%-418.5%-623.3%——
Return on assets-20.4%-3.7%-37.8%-48.5%-34.4%-54.7%-74.9%-38.0%
Return on equity-21.5%-4.0%-41.4%-55.2%-38.2%-74.4%-94.9%51.2%
Current ratio27.4022.6317.7112.4111.774.478.2417.52

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.